Managing OUD in Patients with Severe Mental Illness (SMI)

TL;DR:

• Patients with Severe Mental Illness (SMI) like schizophrenia or bipolar disorder have a high prevalence of co-occurring Opioid Use Disorder (OUD). Treating both conditions concurrently is essential.
• Stabilizing the OUD is foundational. It is exceptionally difficult to manage SMI in the context of chaotic substance use. Opioid Agonist Treatment (OAT) provides the stability needed for psychiatric medications and therapies to be effective.
• OAT is safe and effective in the SMI population. Careful consideration of potential drug interactions (e.g., QTc prolongation with methadone and some antipsychotics) is necessary, but these are manageable.
• Arrow Medical provides low-barrier, harm-reduction-focused OAT that is ideally suited for this population, who often struggle with executive function and appointment adherence. Our walk-in model ensures consistent access to care.

The relationship is bidirectional: the symptoms of SMI can drive substance use as a form of self-medication, and chaotic substance use can exacerbate psychiatric symptoms, leading to decompensation and hospitalization. Treating these conditions in silos is ineffective. An integrated approach that addresses both disorders simultaneously is the standard of care.

The Foundational Role of OAT in Managing Dual-Diagnosis SMI

For a patient with a dual SMI-OUD diagnosis, stabilizing the OUD with Opioid Agonist Treatment (OAT) is a foundational and often prerequisite step to effectively managing their SMI.

When a patient is engaged in the daily cycle of acquiring and using illicit opioids, their life is defined by chaos. It becomes nearly impossible to achieve:

• Medication Adherence: Consistent adherence to antipsychotics or mood stabilizers is difficult.
• Therapeutic Engagement: Meaningful participation in therapy or psychosocial programs is compromised.
• Housing and Financial Stability: These are often precarious.

By providing OAT (methadone or buprenorphine), we remove the chaos of OUD. OAT manages cravings and withdrawal, which frees up the patient’s cognitive and emotional resources to focus on their psychiatric care. It provides the structure and stability upon which a comprehensive mental health treatment plan can be built.

Clinical Considerations and Medication Management

Providing OAT to patients with SMI is safe and highly effective, with a few key considerations.

1. Medication Selection:

• Both methadone and buprenorphine (Suboxone) are effective options.
• Long-acting injectable buprenorphine (Sublocade) can be an excellent choice for this population, as it eliminates the need for daily dosing, which can be a challenge for patients with significant executive dysfunction or paranoia about oral medications.

2. Drug-Drug Interactions:

• QTc Prolongation: The most well-known interaction is the risk of QTc prolongation with methadone, especially when combined with certain antipsychotics (e.g., ziprasidone, haloperidol). A baseline ECG and periodic monitoring are recommended when using these combinations. Buprenorphine does not carry this risk and may be a preferred agent in patients with known cardiac issues or who are on multiple QTc-prolonging agents.
• CYP450 Interactions: Be mindful of potential interactions with enzyme-inducing or -inhibiting medications (e.g., carbamazepine), which may affect methadone levels.

3. Capacity and Consent:

• Patients with SMI are presumed to have the capacity to consent to OAT. A diagnosis of SMI is not, in itself, a reason to deny treatment. The principles of informed consent apply, ensuring the patient understands the risks and benefits to the best of their ability.

The Arrow Medical Model: Low-Barrier Care for Complex Patients

The traditional appointment-based model of healthcare can be a significant barrier for patients with SMI. Our model is designed to overcome these challenges.

• Walk-In Access: We eliminate the need for scheduled appointments, which patients with poor executive function often miss. They can access care whenever they are able.
• Harm Reduction Focus: We meet patients where they are. Our goal is engagement and safety, not enforced abstinence, which is a more realistic and compassionate approach for this complex population.

Frequently Asked Questions for Mental Health Teams

Q: My patient is paranoid and refuses to take oral medication. What can be done?
This is a common challenge. Sublocade (the monthly buprenorphine injection) is an excellent solution. After an initial stabilization period, it reduces the need for daily medication negotiation. Our team is experienced in working with patients to build the trust needed for this transition.

Q: Will OAT interfere with the effectiveness of their psychiatric medications?
No. When dosed appropriately, OAT does not reduce the efficacy of antipsychotics or mood stabilizers. In fact, by stabilizing the OUD, OAT allows these medications to work more effectively in a more stable neurochemical environment.

Q: How do you manage care for patients who are frequently hospitalized?
We work closely with hospital teams to ensure continuity of care. We can help with inpatient initiation and have a seamless process for patients to return to our clinic immediately upon discharge, ensuring there are no gaps in their OAT.

Treating OUD in patients with SMI is not just possible; it is essential. By partnering with Arrow Medical, you can ensure your patients receive expert, low-barrier addiction care that will serve as the foundation for their mental health recovery.